These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 31668345)

  • 1. Prescription Patterns of Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary Intervention With Stent Implantation (from the NCDR PINNACLE Registry).
    Khalid U; Bandeali S; Jones PG; Virani SS; Hira R; Hamzeh I; Chan PS; Kleiman NS; Lakkis N; Alam M
    Am J Cardiol; 2019 Dec; 124(12):1807-1812. PubMed ID: 31668345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
    Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
    Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome.
    Kim K; Lee TA; Touchette DR; DiDomenico RJ; Ardati AK; Walton SM
    J Manag Care Spec Pharm; 2017 Jan; 23(1):57-63. PubMed ID: 28025925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
    Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
    Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of P2Y12 Inhibitors in Acute Coronary Syndromes in the Australian Population.
    Hou M; Hyun K; Chew DP; Kritharides L; Amos D; Brieger D
    Heart Lung Circ; 2022 Aug; 31(8):1085-1092. PubMed ID: 35589483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
    Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
    Wang Z; Zhou DY; Su Y; Si LY; Xu Q
    BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
    Gill K; Servati N; Flahive J; Fraielli K
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):625-629. PubMed ID: 34236915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
    Wang Y; Cavallari LH; Brown JD; Thomas CD; Winterstein AG
    JAMA Netw Open; 2023 Apr; 6(4):e238585. PubMed ID: 37067798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial.
    Welsh RC; Sidhu RS; Cairns JA; Lavi S; Kedev S; Moreno R; Cantor WJ; Stankovic G; Meeks B; Yuan F; Džavík V; Jolly SS
    Can J Cardiol; 2019 Oct; 35(10):1377-1385. PubMed ID: 31492492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y
    Choe JC; Cha KS; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH;
    Int J Cardiol; 2019 Jan; 274():21-26. PubMed ID: 30224257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel and Ticagrelor in Patients with Drug-Eluting Stents and Kidney Failure.
    Mavrakanas TA; Kamal O; Charytan DM
    Clin J Am Soc Nephrol; 2021 May; 16(5):757-764. PubMed ID: 33811128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
    Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
    JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database.
    Sirker A; Kwok CS; Kontopantelis E; Johnson T; Freeman P; de Belder MA; Ludman P; Zaman A; Mamas MA
    Catheter Cardiovasc Interv; 2018 Oct; 92(4):659-665. PubMed ID: 29356278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor.
    Motovska Z; Hlinomaz O; Kala P; Hromadka M; Knot J; Varvarovsky I; Dusek J; Jarkovsky J; Miklik R; Rokyta R; Tousek F; Kramarikova P; Svoboda M; Majtan B; Simek S; Branny M; Mrozek J; Cervinka P; Ostransky J; Widimsky P;
    J Am Coll Cardiol; 2018 Jan; 71(4):371-381. PubMed ID: 29154813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study.
    Godtfredsen SJ; Kragholm KH; Leutscher P; Jørgensen SH; Christensen MK; Butt JH; Gislason G; Køber L; Fosbøl EL; Sessa M; Bhatt DL; Torp-Pedersen C; Pareek M
    Eur Heart J Acute Cardiovasc Care; 2022 Sep; 11(9):697-705. PubMed ID: 35950769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends for and Clinical Factors Associated with Choice of Oral P2Y
    Jain N; Hunt SL; Cui H; Phadnis MA; Mahnken JD; Shireman TI; Dai J; Mehta JL; Rasu RS
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):511-521. PubMed ID: 31729588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.
    Dayoub EJ; Seigerman M; Tuteja S; Kobayashi T; Kolansky DM; Giri J; Groeneveld PW
    JAMA Intern Med; 2018 Jul; 178(7):943-950. PubMed ID: 29799992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prasugrel or ticagrelor in patients with acute coronary syndrome and diabetes: a propensity matched substudy of RENAMI.
    Conrotto F; Bertaina M; Raposeiras-Roubin S; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Flores Blanco P; Garay A; Quadri G; Varbella F; Caneiro Queija B; Cobas Paz R; Cespón Fernández M; Muñoz Pousa I; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Abu-Assi E; D'Ascenzo F
    Eur Heart J Acute Cardiovasc Care; 2019 Sep; 8(6):536-542. PubMed ID: 30270638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.